Government-Owned Inventions; Availability for Licensing, 62514-62515 [2016-21699]
Download as PDF
asabaliauskas on DSK3SPTVN1PROD with NOTICES
62514
Federal Register / Vol. 81, No. 175 / Friday, September 9, 2016 / Notices
Institute of Environmental Health
Sciences, 111 T.W. Alexander Drive,
P.O. Box 12233, Research Triangle Park,
NC 27709.
SUPPLEMENTARY INFORMATION:
Request for Information: NTP requests
information on four substances that
have been nominated for possible
review for future editions of the RoC
(see https://ntp.niehs.nih.gov/go/
rocnom); three of these four substances
are also under consideration for
evaluation of non-cancer health
outcomes (see https://ntp.niehs.nih.gov/
go/763346). The four nominations are:
• Consumption of red meat: cancer
and non-cancer health hazard
evaluations.
• Consumption of processed meat:
cancer and non-cancer health hazard
evaluations.
• Consumption of meat cooked at
high temperatures: cancer and noncancer health hazard evaluations.
• Antimony trioxide: cancer hazard
evaluation.
Cancer hazard evaluation of a
substance for the RoC may seek to list
a new substance in the report, reclassify
the listing status of a substance already
listed, or remove a listed substance.
Specifically, NTP requests
information on: (1) Current production,
use patterns, and human exposure
estimates for antimony trioxide; (2) data
on dietary intake estimates of red meat,
processed meat, or meat cooked at high
temperatures; and for all four
nominations (3) recently published,
ongoing, or planned studies related to
evaluating adverse health outcomes
(e.g., cancer, development,
reproductive, or immunological
disorders); (4) scientific issues
important for prioritizing and assessing
adverse health outcomes; and (5) names
of scientists with expertise or
knowledge on any of these substances—
please indicate the substance and
include any bibliographic citations
when available. NTP will use this
information in determining which
substances to propose for formal health
hazard evaluations.
Information on substances for
possible review should be submitted
electronically at https://
ntp.niehs.nih.gov/go/778417 or emailed
to Dr. Lunn or Dr. Boyd (see FOR
FURTHER INFORMATION CONTACT). Contact
information for comments should
include the submitter’s name,
affiliation, sponsoring organization (if
any), telephone, and email. Written
information received in response to this
notice will be posted on the NTP Web
site, and the submitter identified by
name, affiliation, and/or sponsoring
VerDate Sep<11>2014
17:11 Sep 08, 2016
Jkt 238001
organization. Guidelines for public
comments are at https://
ntp.niehs.nih.gov/ntp/about_ntp/
guidelines_public_comments_508.pdf.
Responses to this request for
information are voluntary. This request
for information is for planning purposes
only and is not a solicitation for
applications or an obligation on the part
of the U.S. Government to provide
support for any ideas identified in
response to it. Please note that the U.S.
Government will not pay for the
preparation of any information
submitted or for its use. No proprietary,
classified, confidential, or sensitive
information should be included in your
response.
Background Information on ORoC: On
behalf of NTP, ORoC prepares the RoC
following an established, four-part
process (https://ntp.niehs.nih.gov/go/
rocprocess). The RoC is a
congressionally mandated, sciencebased, public health report that
identifies agents, substances, mixtures,
or exposures (collectively called
‘‘substances’’) in our environment that
pose a cancer hazard for people in the
United States. Published biennially,
each edition of the RoC is cumulative
and consists of substances newly
reviewed in addition to those listed in
previous editions. Newly reviewed
substances with their recommended
listing are reviewed and approved by
the Secretary of Health and Human
Services. The 13th RoC, the latest
edition, was published on October 2,
2014 (available at https://
ntp.niehs.nih.gov/go/roc13). The 14th
RoC is under development.
Background Information on OHAT:
On behalf of NTP, OHAT conducts
literature-based evaluations to assess the
evidence whether environmental
chemicals, physical substances, or
mixtures (collectively called
‘‘substances’’) cause adverse non-cancer
health outcomes. As part of these
evaluations, NTP may also provide
opinions on whether these substances
might be of concern for causing adverse
effects on human health given what is
known about toxicity and current
human exposure levels. Information
about OHAT can be found at https://
ntp.niehs.nih.gov/go/ohat.
Dated: September 6, 2016.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2016–21698 Filed 9–8–16; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive, Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Reagent for Mapping Genome-Wide
Enhancer-Promoter Interactions
This invention is a research reagent
named the ‘‘bivalent Tn5 complex’’
used in transposition-mediated analysis
of chromatin looping (TrAC-looping) to
determine genome-wide enhancerpromoter interactions during studies of
4D nucleomes in normal development
and disease conditions. Enhancerpromoter interactions are key in
temporospatial control of gene
expression during normal development
and pathological conditions. Currently
available methods of analyzing genomewide enhancer-promoter interactions
are insufficient in achieving necessary
resolution, give rise to false positive
artifacts due to in vitro ligation steps, or
too expensive due to the necessity of
sequencing over a billion reads. The
instant reagent and associated TrAClooping technique effectively reduce
false positive detection and achieve a 10
to 100-times higher resolution at lower
cost for mapping genome-wide
interactions between enhancers and
promotes essential for the control of
gene expression in normal development
and pathological conditions.
References
—Lieberman-Aiden E et al., Science
2009 Oct 9;326(5950):289–93.
E:\FR\FM\09SEN1.SGM
09SEN1
Federal Register / Vol. 81, No. 175 / Friday, September 9, 2016 / Notices
—Rao S et al., Cell. 2014 Dec
18;159(7):1665–80.
—Goryshin et al., JBC 1998 March
273(13) 7367–7374.
Potential Commercial Applications
—Genome wide Enhancer-Promoter
mapping
—Functional annotation of genomic
structure
—Three-dimensional chromatin
organization
—Analysis of 4D Nucleomes during
development of diseases
—Identification of key genomic
sequences involved in diseases
—Diagnostic for diseases associated
with aberrant gene expression
Competitive Advantages
—Transposition mediated analysis of
chromatin looping
Development Stage: Research reagent.
Inventors: Keji Zhao and Qingsong
Tang (both of NHLBI).
Intellectual Property: HHS Reference
No. E–266–2016/0;—Research reagent.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Dated: September 2, 2016.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2016–21699 Filed 9–8–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Conclusion of the National Customs
Automation Program (NCAP) Test
Concerning the Submission of Data
Required by the Food Safety and
Inspection Service (FSIS) in the
Automated Commercial Environment
(ACE)
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: General notice.
AGENCY:
This document announces the
conclusion of the National Customs
Automation Program (NCAP) test
concerning the electronic transmission
of certain import data required by the
Food Safety and Inspection Service
(FSIS) to the Automated Commercial
Environment (ACE) using the Partner
Government Agency (PGA) Message Set.
U.S. Customs and Border Protection
(CBP) has determined that the NCAP
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:11 Sep 08, 2016
Jkt 238001
62515
test has been a success, as ACE has
proven capable of receiving and
processing the data required by FSIS,
and sharing that data with FSIS.
Accordingly, this NCAP test will be
concluded on October 11, 2016. CBP has
made ACE the sole CBP-authorized
electronic data interchange (EDI) system
for most entry and entry summary
filings, including entry and entry
summary filings for meat, poultry and
egg products regulated by FSIS. As a
result, filers transmitting electronic
import data required by FSIS with their
electronic entry or entry summary must
use ACE.
DATES: The NCAP test will conclude on
October 11, 2016.
ADDRESSES: Comments concerning this
notice and any aspect of this test may
be submitted via email to Josephine
Baiamonte, ACE Business Office (ABO),
Office of Trade, at
josephine.baiamonte@cbp.dhs.gov.
FOR FURTHER INFORMATION CONTACT: For
CBP-related questions, contact Jeffrey
Nii, Director, Inter-Agency
Collaboration Division, Office of Trade,
at jeffrey.c.nii@cbp.dhs.gov.
SUPPLEMENTARY INFORMATION:
announcing its plan to begin a phased
decommissioning of ACS for entry and
entry summary filings, making ACE the
sole CBP-authorized electronic data
interchange (EDI) system for processing
those electronic filings. See 81 FR 10264
(February 29, 2016). As part of this
phased decommissioning, CBP
announced that ACE would become the
sole CBP-authorized EDI for processing
certain electronic entries and entry
summaries for merchandise subject to
the import requirements of the Food and
Drug Administration on June 15, 2016.
See 81 FR 30320 (May 16, 2016). On
July 23, 2016, CBP completed this
phased decommissioning, and ACE
became the sole CBP-authorized EDI
system for most entry and entry
summary filings for all filers. See 81 FR
32339 (May 23, 2016). Entries and entry
summaries for the entry types specified
in the May 23, 2016 notice, including
entries and entry summaries
accompanied by data required by the
Food Safety and Inspection Service
(FSIS), must be filed in ACE. ACS is no
longer available for these filings.
I. Background
The National Customs Automation
Program (NCAP) was established by
Subtitle B of Title VI—Customs
Modernization, in the North American
Free Trade Agreement Implementation
Act (Pub. L. 103–182, 107 Stat. 2057,
December 8, 1993) (Customs
Modernization Act). See 19 U.S.C. 1411.
Through NCAP, the thrust of customs
modernization was on trade compliance
and the development of the Automated
Commercial Environment (ACE), the
planned successor to the legacy
Automated Commercial System (ACS).
ACE is an automated and electronic
system for commercial trade processing.
ACE will streamline business processes,
facilitate growth in trade, ensure cargo
security, and foster participation in
global commerce, while ensuring
compliance with U.S. laws and
regulations and reducing costs for U.S.
Customs and Border Protection (CBP)
and its communities of interest. The
ability to meet these objectives depends
upon successfully modernizing CBP’s
business functions and the information
technology that supports those
functions. CBP’s modernization efforts
are accomplished through phased
releases of ACE component
functionality, designed to introduce a
new capability or to replace a specific
legacy ACS function.
On February 29, 2016, CBP published
a notice in the Federal Register
The Partner Government Agency
(PGA) Message Set is the data required
to satisfy a PGA’s reporting
requirements through ACE. It enables
the trade community to submit traderelated data required by the PGA only
once to CBP, thus improving
communications between the agency
and filers, and shortening entry
processing time. Also, by virtue of being
electronic, the PGA Message Set
eliminates the necessity for the
submission and subsequent manual
processing of paper documents.
Through the Customs Modernization
Act and section 101.9 of title 19 of the
Code of Federal Regulations (19 CFR
101.9(b)), the Commissioner of CBP has
authority to conduct limited test
programs or procedures designed to
evaluate planned components of the
NCAP. See Treasury Decision (T.D.) 95–
21.
On December 13, 2013, CBP
published a notice in the Federal
Register announcing CBP’s plan to
conduct an NCAP test concerning the
electronic transmission of the PGA
Message Set data elements required by
FSIS for the importation of certain meat,
poultry, and egg products to CBP
through ACE. See 78 FR 75931
(December 13, 2013). Under this test,
the PGA Message Set satisfied the FSIS
data requirements for electronic entries
filed in ACE and enabled the trade
community to use the CBP-managed
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
II. The Partner Government Agency
Message Set Test for FSIS Data
E:\FR\FM\09SEN1.SGM
09SEN1
Agencies
[Federal Register Volume 81, Number 175 (Friday, September 9, 2016)]
[Notices]
[Pages 62514-62515]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21699]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the indicated licensing contact at the National Heart,
Lung, and Blood, Office of Technology Transfer and Development Office
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda,
MD 20892-2479; telephone: 301-402-5579. A signed Confidential
Disclosure Agreement may be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION: Technology description follows.
Reagent for Mapping Genome-Wide Enhancer-Promoter Interactions
This invention is a research reagent named the ``bivalent Tn5
complex'' used in transposition-mediated analysis of chromatin looping
(TrAC-looping) to determine genome-wide enhancer-promoter interactions
during studies of 4D nucleomes in normal development and disease
conditions. Enhancer-promoter interactions are key in temporospatial
control of gene expression during normal development and pathological
conditions. Currently available methods of analyzing genome-wide
enhancer-promoter interactions are insufficient in achieving necessary
resolution, give rise to false positive artifacts due to in vitro
ligation steps, or too expensive due to the necessity of sequencing
over a billion reads. The instant reagent and associated TrAC-looping
technique effectively reduce false positive detection and achieve a 10
to 100-times higher resolution at lower cost for mapping genome-wide
interactions between enhancers and promotes essential for the control
of gene expression in normal development and pathological conditions.
References
--Lieberman-Aiden E et al., Science 2009 Oct 9;326(5950):289-93.
[[Page 62515]]
--Rao S et al., Cell. 2014 Dec 18;159(7):1665-80.
--Goryshin et al., JBC 1998 March 273(13) 7367-7374.
Potential Commercial Applications
--Genome wide Enhancer-Promoter mapping
--Functional annotation of genomic structure
--Three-dimensional chromatin organization
--Analysis of 4D Nucleomes during development of diseases
--Identification of key genomic sequences involved in diseases
--Diagnostic for diseases associated with aberrant gene expression
Competitive Advantages
--Transposition mediated analysis of chromatin looping
Development Stage: Research reagent.
Inventors: Keji Zhao and Qingsong Tang (both of NHLBI).
Intellectual Property: HHS Reference No. E-266-2016/0;--Research
reagent.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
shmilovm@mail.nih.gov.
Dated: September 2, 2016.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2016-21699 Filed 9-8-16; 8:45 am]
BILLING CODE 4140-01-P